In EPTB patients, only FL-Gal9 was significantly decreased at the end of therapy, and FL-Gal9 levels at the second visit serve as a marker of therapeutic efficacy (high INS), indicating its role in monitoring treatment success in EPTB patients irrespective of the site of infection. This evidence concerns the gene LGALS9 and infection.